Pharmaceutical packaging industry leaders form the Matrix Alliance to help manufacturers speed breakthrough treatments to market
Compatibility and testing of nested container and closure systems to help pharmaceutical companies manufacture parenteral medicines.
As next-generation drugs require perfectly aligned manufacturing processes and packaging solutions, leading suppliers have announced the creation of the Matrix Alliance. Their mission is to bring to market complete and compelling solutions for aseptic filling, consisting of nest, stopper, cap and filling machinery to accelerate the adoption rate of breakthrough medicines.
The Alliance was formed on the initiative of Vanrx Pharmasystems with inaugural members ARaymond Life, Daikyo Seiko, Datwyler Group, Ompi, Schott AG, Schott Kaisha and SiO2 Medical Products. Each member brings unique knowledge and experience to the Alliance, as well as industry-leading products. As part of the collaboration, members will leverage the testing and certification of their combined offerings. The Alliance is also a forum providing strategic direction, education, and awareness of new aseptic packaging solutions within the membership and to the market.
The companies are collectively focused on pharmaceutical manufacturing and packaging technologies, and have reached an agreement to work in four key areas:
"The need for collaboration in this area arises from the increasing sophistication of manufacturing processes and packaging needed for next-generation parenteral pharmaceuticals. Emerging categories of complex, high-value injectable drugs share the need for innovation in fill / finish and packaging. We believe that collaboration will speed the path of new therapies to the market by our customers, the pharmaceutical companies," Alliance members said in a joint statement.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.